Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?

Dianthus Therapeutics, Inc. DNTH shares soared 5.6% in the last trading session to close at $83.92. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 43.8% gain over the past four weeks.

This rise in share price is attributed to positive investor expectations around its pipeline. The stock has been surging over the past month after the company announced an early “GO” decision in the late-stage CAPTIVATE study evaluating claseprubart for a rare autoimmune disease called chronic inflammatory demyelinating polyneuropathy (CIDP). This decision came ahead of schedule as the company hit its interim responder goals.

Dianthus’ shares received an additional boost last week after the FDA agreed to several proposed changes related to clinical development of claseprubart, including updates to screening criteria, routine lab work and autoimmune safety monitoring. These changes apply to all ongoing and future studies.

This company is expected to post quarterly loss of $1.17 per share in its upcoming report, which represents a year-over-year change of -42.7%. Revenues are expected to be $0.55 million, down 53% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Dianthus Therapeutics, Inc., the consensus EPS estimate for the quarter has been revised 27.6% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on DNTH going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Dianthus Therapeutics, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Foghorn Therapeutics Inc. FHTX, finished the last trading session 8.1% higher at $4.78. FHTX has returned -23.3% over the past month.

For Foghorn Therapeutics, the consensus EPS estimate for the upcoming report has changed -7.7% over the past month to -$0.28. This represents a change of +6.7% from what the company reported a year ago. Foghorn Therapeutics currently has a Zacks Rank of #3 (Hold).

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Dianthus Therapeutics, Inc. (DNTH): Free Stock Analysis Report

Foghorn Therapeutics Inc. (FHTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research